Mike Dybbs

Partner at Samsara BioCapital · Joined 2017

Biography

Mike Dybbs, Ph.D. has been a Partner at Samsara BioCapital since the fund was launched in 2017, and is named as a Managing Member of the fund's general partner in the Samsara BioCapital, L.P. Form D filed on 21 March 2017. Before Samsara he was a Partner at New Leaf Venture Partners, where the firm states he served on the boards of Versartis, Dimension Therapeutics, Advanced Cell Diagnostics (acquired by Bio-Techne) and Principia (acquired by Sanofi), and before that a Principal at the Boston Consulting Group and a core member of its health care practice. He received an A.B. in biochemical sciences from Harvard and a Ph.D. in molecular biology from UC Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. Samsara's team page states that he currently serves on the boards of Kalaris, Nkarta Therapeutics and Sutro among Samsara portfolio companies, plus several private companies; the Nkarta seat is independently confirmed by Nkarta's 2026 proxy statement.

Education

• A.B. in biochemical sciences, Harvard University
• Ph.D. in molecular biology, University of California, Berkeley (Howard Hughes Medical Institute fellowship)

Previous Experience

• Boston Consulting Group, Principal, core member of the health care practice
• New Leaf Venture Partners, Partner

Notable Investments

Board Seats

• Kalaris Therapeutics, Inc. (Nasdaq: KLRS), Board member
• Nkarta, Inc. (Nasdaq: NKTX), Board member since August 2019, Chair of the Compensation Committee
• Sutro Biopharma, Inc. (Nasdaq: STRO), Board member

Career Timeline

Sources & References